7 F-Rated Stocks to Avoid at All Costs in June

InvestorPlace06-06

Meet Louis Navellier Lucid Motors (LCID): Only vehicle sales to the Saudi Arabian government (which owns a 60% stake in LCID) helped Lucid beat expectations last quarter. Akoustis Technologies ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2441792427?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-06 18:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2441792427","market":"us","top_or_hot":-1,"title":"7 F-Rated Stocks to Avoid at All Costs in June","media":"InvestorPlace","content":"<div>\n<p>Meet Louis Navellier\t\t\n\n\n\n\n\nLucid Motors (LCID): Only vehicle sales to the Saudi Arabian government (which owns a 60% stake in LCID) helped Lucid beat expectations last quarter.\nAkoustis Technologies ...</p>\n\n<a href=\"https://investorplace.com/market360/2024/06/7-f-rated-stocks-to-avoid-at-all-costs-in-june/\">Source Link</a>\n\n</div>\n","source":"investorplace_stock_picks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 F-Rated Stocks to Avoid at All Costs in June</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 F-Rated Stocks to Avoid at All Costs in June\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-06 18:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/market360/2024/06/7-f-rated-stocks-to-avoid-at-all-costs-in-june/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Meet Louis Navellier\t\t\n\n\n\n\n\nLucid Motors (LCID): Only vehicle sales to the Saudi Arabian government (which owns a 60% stake in LCID) helped Lucid beat expectations last quarter.\nAkoustis Technologies ...</p>\n\n<a href=\"https://investorplace.com/market360/2024/06/7-f-rated-stocks-to-avoid-at-all-costs-in-june/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4574","symbol_name":"无人驾驶","start_time":0,"source_url":"https://investorplace.com/market360/2024/06/7-f-rated-stocks-to-avoid-at-all-costs-in-june/","article_id":"2441792427","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2441792427","pubTimestamp":1717670700,"sourceInfo":{"source_id":"investorplace_stock_picks","name":"InvestorPlace stock picks"},"weMediaInfo":null,"summary":"For many people, the most important thing about investing is knowing which stocks to buy, and when to buy them. If you’re a buy-and-hold investor,…","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4574":"无人驾驶","LCID":"Lucid Group Inc","BK4551":"寇图资本持仓","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0056508442.USD":"贝莱德世界科技基金A2","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","BK4581":"高盛持仓","QID":"纳指两倍做空ETF","MULN":"Mullen Automotive","VSTM":"Verastem","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4511":"特斯拉概念","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","PSQ":"纳指反向ETF","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","BK4548":"巴美列捷福持仓","LU2063271972.USD":"富兰克林创新领域基金","TAK":"武田制药","BSFC":"BLUE STAR FOODS CORP.","TQQQ":"纳指三倍做多ETF","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC",".IXIC":"NASDAQ Composite","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU0823414478.USD":"法巴经典能源转换基金","QLD":"纳指两倍做多ETF","LU0097036916.USD":"贝莱德美国增长A2 USD","BK4212":"包装食品与肉类","BK4592":"伊斯兰概念","QQQ":"纳指100ETF","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","SQQQ":"纳指三倍做空ETF","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","BK4534":"瑞士信贷持仓","LU1861215975.USD":"贝莱德新一代科技基金 A2","LU1548497426.USD":"安联环球人工智能AT Acc","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4007":"制药","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","BK4527":"明星科技股","HLTH":"Cue Health Inc.","AKTS":"Akoustis Technologies Inc","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC"},"translate_title":"6月份要不惜一切代价避开的7只F级股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKTS":1,"VSTM":1,"TAK":1,"MULN":1,"LCID":1,"HLTH":1,"BSFC":1,".IXIC":0.9,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"SQQQ":0.6,"TQQQ":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"Meet Louis Navellier\t\t\n\n\n\n\n\nLucid Motors (LCID): Only vehicle sales to the Saudi Arabian government (which owns a 60% stake in LCID) helped Lucid beat expectations last quarter.\nAkoustis Technologies (AKTS): Akoustis is selling 50 million shares of new stock to raise $10 million.\nVerastem (VSTM): The stock dropped 56% when the company announced it was seeking FDA approval for a new cancer treatment.\nKeep reading for more F-rated stocks to avoid!\n\n\n\n\n\n \n\n\nFor many people, the most important thing about investing is knowing which stocks to buy, and when to buy them. If you’re a buy-and-hold investor, then you’re going to keep your picks for a long time. If you’re a more active trader, then you’re also looking for the perfect time to take your profits and move on. \nIt’s critically important for any investor to also be able to recognize which stocks to avoid – because those are the stocks that will wreck your portfolio if given the chance.\nThis has been an interesting year in the market so far. Tech stocks are continuing to rule the day, with the tech-heavy Nasdaq composite up nearly 10% on the year. The S&P 500 is doing well as well, up 7%. Meanwhile, the benchmark Dow Jones Industrial Average shows only a 2% gain for the year.\nWith those kinds of gains on the table, it would be tragic to bury your money into F-rated stocks. The “F” rating comes from the Portfolio Grader – a free service that evaluates stocks on an “A” through “F” scale based on growth, earnings performance, analyst sentiment and trading momentum.\nNo tool is infallible, but I’ve found the Portfolio Grader to be an ideal system to help investors of all stripes ferret out which stocks are worth your attention and which ones are stocks to avoid. The names on this list definitely fall within the latter category.\nLucid Motors (LCID)\nSource: Around the World Photos / Shutterstock.comIt’s an easy choice to kick off any list of stocks to avoid with the struggling electric vehicle company Lucid Motors (NASDAQ:LCID). Once thought to be a legitimate rival to Tesla (NASDAQ:TSLA), Lucid has failed to scale its business and is a major disappointment.\nHow can any company be considered a possible Tesla killer when it only produced 6,001 vehicles last year? In the first quarter of this year, Lucid manufactured another 1,728 vehicles and delivered 1,967.\nBulls will point out that Lucid managed to beat expectations for revenue in the first quarter, bringing in $173 million versus the expected $154 million. But that was only because of Lucid’ vehicle sales to the Saudi Arabian government. When you look at external customers, demand for Lucid vehicles is falling. (Saudi Arabia’s Public Investment Fund has a 60% stake in Lucid.)\nLCID stock is down 32% this year and gets an “F” rating in the Portfolio Grader.\nAkoustis Technologies (AKTS)\nSource: shutterstock.com/Pla2naAkoustis Technologies (NASDAQ:AKTS) is a North Carolina company that designs, develops, manufactures and sells radio frequency filter products. It operates a 125,000-square-foot wafer manufacturing facility in New York to design and build filters and other semiconductor devices.\nBut its most recent earnings report was a major disappointment. Revenue in the third fiscal quarter of 2024 was $7.51 million, up 2.1% from a year ago, but missed analyst estimates by 12%.\nThe company posted a net loss of $23.3 million, which was a 50% increase from a year ago, and lost 26 cents per share versus a loss of 23 cents per share a year ago. The EPS mark was particularly disappointing, as it missed analysts’ estimates by 86%.\nThe quarter ended with Akoustis having only $15.2 million on cash on hand and assets of $28.5 million, down from $43.1 million in cash and total assets of $59.8 million a year ago. So is no surprise that Akoustis is now selling an additional 50 million shares of stock, priced at 20 cents per share, in an effort to raise $10 million to fund operations.\nAKTS stock is down 79% this year and gets an “F” rating in the Portfolio Grader.\nVerastem (VSTM)\nSource: ShutterstockVerastem (NASDAQ:VSTM) is a biopharmaceutical company that is working on treatments for cancer. The company is focused specifically on RAS pathway-driven cancers and is developing treatments targeted toward mutated RAS genes.\nVerastem is seeking FDA approval for avutometinib and defactinib combination for patients with recurrent KRAS gene mutant low-grade serous ovarian cancer. The rolling review process allows the company to submit completed sections of an application for FDA review before all sections are available.\nWhile this could be a great breakthrough for patients, investors would be wise to be cautious. Clinical trials and FDA approval are costly, time-consuming, and sometimes yield no results. Developing a breakthrough drug can lead to highly profitable rewards.\nVerastem has $110.1 million in cash at the end of the first quarter, having losing $33.9 million in the period. Research and development costs were $17.7 million, and selling, general and administrative expenses were $10.4 million.\nThe company is investing more in preparation for a potential launch of avutometinib and defactinib treatment. The stock price dropped 59% when it announced its FDA approval plans. \nOnce trading as high as $14 per share, VSTM stock is down to penny stock territory now, having lost 56% in value so far on the year. It gets an “F” rating in the Portfolio Grader.\nMullen Automotive (MULN)\nSource: rafapress / Shutterstock.comMullen Automotive (NASDAQ:MULN) is another struggling electric vehicle company. \nLike Lucid, it had high expectations that it would challenge Tesla, and its encountered similar issues with trying to scale the business to make a dent in the EV field.\nMullen had a wild 2023 just trying to stay relevant. On three separate occasions it triggered a reverse stock split to keep the stock price over $1 per share and maintain Nasdaq compliance. The last of those splits was a 1-for-100 split that on paper pushed the stock price higher. But in reality, the value of Mullen shares fell by 99% over the course of the year.\nMullen’s strategy is now to go into commercial EVs. Its expanding its distribution network into Eastern Europe and it signed a new deal to supply 40 commercial vehicles to a company in Switzerland. Mullen also completed the first phase of its battery line integration at its California plant in hopes of commercializing EV battery packs.\nWhile it finally saw some revenue in the second quarter of fiscal 2024 — $33,000 – it also saw losses of $177.3 million. And now with only $22.3 million in cash and cash equivalents left, Mullen will need to find more funding if it’s going to keep up this level of cash burn.\nMULN stock is down 73% this year and gets an “F” rating in the Portfolio Grader.\nTakeda Pharmaceutical (TAK)\nSource: Sisacorn / Shutterstock.comTakeda Pharmaceutical (NYSE:TAK) is a Japanese pharmaceutical company that has a large presence in the U.S. as well. The company traces its roots back to the 18th century and currently operates in 80 countries.\nIts top-selling drug is Entyvio, which treats patients with ulcerative colitis and Crohn’s disease. Revenues in 2022 for Entyvio were $4.5 billion.\nIt also makes Vynanse, which is a popular drug for attention deficit disorder. But it lost exclusivity for the drug in 2023 and generic competitors are now on the market.\nEarnings for 2023 were 4.26 trillion yen, ($272.6 billion), up 5.9% from a year ago. But net profit was 144 billion yen and EPS was 92 billion yen, both down 54% from a year ago.\nTakeda forecast 2024 revenue of 4.35 trillion yen, with core revenue flat to slightly declining. It also forecast a 10% decline in operating profit and an EPS decline in the mid-10%.\nTAK stock is down 6% this year but doesn’t have a strong growth story for 2024. It gets an “F” rating in the Portfolio Grader.\nCue Health (HLTH)\nSource: ShutterstockCue Health (NASDAQ:HLTH) is a tiny health care company with a market capitalization of only $9 million. The San Diego-based company provides a platform that provides patients and health care workers with access to lab-quality diagnostic tests at home and in a doctor’s office.\nIts Covid-19 test was the first home use respiratory tests to get approval from the FDA.\nUnfortunately for Cue, people aren’t testing for Covid-19 in 2024 at the same frequency they were in the last few years. In addition, Cue received a warning letter in May from the FDA about its home Covid-19 tests. \nThe letter alleged that the company made changes to the test without approval from the government oversight agency. The FDA issued a public statement saying not to use the Cue test because it could issue a false result.\nCue says it’s evaluating the letter but has not made a further comment. It was scheduled to issue its first-quarter earnings report on May 13 but has not done so.\nHLTH stock is down 62% this year and gets an “F” rating in the Portfolio Grader.\nBlue Star Foods (BSFC)\nSource: ShutterstockBlue Star Foods (NASDAQ:BSFC) is a Miami-based seafood company. It imports, packages and sells crab meat and salmon in many major grocery stores throughout the U.S.\nBut with a limited product base, Blue Star has some inherent risks. The population of crab can fluctuate because of disease or biological issues. Market demand can also factor into Blue Star earnings. In addition, the worldwide supply of natural fish is dropping and causing many countries to limit the amount of seafood that can be caught and harvested.\nBlue Star had revenue of $2.3 million in the first quarter, up from $1.9 million a year ago. The net loss was $1.1 million, from a loss of $2 million in the same quarter a year ago.\nBlue Star, which recently executed a reverse 1-for-50 stock split to keep its stock price in compliance with Nasdaq listing rules, is down 68% this year. It gets an “F” rating in the Portfolio Grader.\nOn the date of publication, neither Louis Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.\nBiotech, Consumer Discretionary, Automotive, Electric Vehicles, Consumer Staples, Food, Healthcare, Industrial\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\n Louis Navellier\nEditor, Market 360\n\n\nMeet Louis Navellier\nLouis Navellier is one of Wall Street’s renowned growth investors. Providing investment advice to tens of thousands of investors for more than three decades, he has earned a reputation as a savvy stock picker and unrivaled portfolio manager.\n\n\n\t\t\t\tLearn more about Louis\t\t\t\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/market360/2024/06/7-f-rated-stocks-to-avoid-at-all-costs-in-june/.\n©2024 InvestorPlace Media, LLC","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2441792427"}